Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
Ottawa Heart Institute Research Corporation
1,800 participants
Oct 3, 2018
INTERVENTIONAL
Conditions
Summary
Coronary angiography is performed to evaluate for obstructive coronary artery disease. This is commonly performed via the transfemoral or transradial approach with the latter increasing in frequency. One of the most common complications of transradial access is radial artery occlusion occurring in \~5% of patients which prohibits the use of the radial artery in the future. There is evidence to support the use of intraprocedural anticoagulation to mitigate the risk of radial artery occlusion however the role of post-procedural anticoagulation has not been previously evaluated. Rivaroxaban is a direct oral anticoagulant (DOAC) with a safety profile superior to that of vitamin K antagonists. Given the safety profile, ease of use, and feasibility of DOAC therapy, our study will endeavor to evaluate the use of rivaroxaban 15mg orally once daily for 7 days after transradial access and the impact this has on the rate of radial artery occlusion.
Eligibility
Inclusion Criteria3
- Willing and able to provide written informed consent
- Age ≥ 18 years
- Diagnostic coronary angiography or percutaneous coronary intervention via the transradial approach
Exclusion Criteria24
- Presence of a palpable hematoma or clinical concern of hemostasis at the transradial access site
- Access or attempted access at a second site - including contralateral radial artery, brachial, or femoral artery or vein
- Planned staged procedure, CABG or noncardiac surgery within 30 days
- Contraindication or high risk of bleeding with anticoagulation
- bleeding requiring medical attention in the previous 6 months
- thrombocytopenia (platelets\<50 x 109/L)
- prior intracranial hemorrhage
- use of IIb/IIIa during percutaneous coronary intervention
- administration of thrombolytic therapy in the preceding 24 hours
- use of non-steroidal anti-inflammatory medications
- ischemic stroke or transient ischemic attack diagnosed in the last 3 months
- Cardiogenic shock
- Ventricular arrhythmias refractory to treatment
- Liver dysfunction (Child-Pugh class B or C)
- Unexplained anemia with a Hgb below 100 g/L
- History of medication noncompliance or risk factor for noncompliance
- Active malignancy
- Allergy to rivaroxaban
- Another indication for anticoagulation
- CYP3A4 and P-glycoprotein inhibitor use
- Life expectancy \<30 days
- Women capable of pregnancy not on birth control
- Chronic kidney disease with creatinine clearance of less than 30mL/min
- History of antiphosphopholipid antibody syndrome
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will receive rivaroxaban 15mg orally daily for 7 days following transradial access.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03630055